Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human TGFBR1 Anticorps:
anti-Mouse (Murine) TGFBR1 Anticorps:
anti-Rat (Rattus) TGFBR1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal TGFBR1 Primary Antibody pour IF (p), IHC (p) - ABIN671256
Xie, Chen, Miao, Tang, Fu: Regulation of cellular behaviors of fibroblasts related to wound healing by sol-gel derived bioactive glass particles. dans Journal of biomedical materials research. Part A 2016
Show all 3 Pubmed References
Human Polyclonal TGFBR1 Primary Antibody pour IHC (p), WB - ABIN392279
Miles, Tung, Aguiar, Kurtoglu, Sikes: Increased TGF-?1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling. dans The Prostate 2012
Show all 2 Pubmed References
Human Polyclonal TGFBR1 Primary Antibody pour IF, WB - ABIN317892
Yu, Hu, Yang, Takemori, Li, Zheng, Hong, Liao, Wen: Salt-inducible kinase 1 is involved in high glucose-induced mesangial cell proliferation mediated by the ALK5 signaling pathway. dans International journal of molecular medicine 2013
Human Polyclonal TGFBR1 Primary Antibody pour ELISA, WB - ABIN563176
Matsunobu, Torigoe, Ishikawa, de Vega, Kulkarni, Iwamoto, Yamada: Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. dans Developmental biology 2009
Mouse (Murine) Monoclonal TGFBR1 Primary Antibody pour FACS - ABIN4896299
Bodogai, Moritoh, Lee-Chang, Hollander, Sherman-Baust, Wersto, Araki, Miyoshi, Yang, Trinchieri, Biragyn: Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. dans Cancer research 2015
results suggest a role for prostatic expression of TGF-B, IL-1a (Montrer IL1A Anticorps), TGFBRI and TGFBRII as prognostic markers for prostate cancer. The rational combination of novel agents directed toward the inactivation of TGF-B, IL-1a (Montrer IL1A Anticorps), TGFBRI and TGFBRII could disrupt complementary tumor cell proliferation pathways.
Data show that twist-related protein 1 (Twist1 (Montrer TWIST1 Anticorps)) requires TGF-beta type-I receptor (TGFBR1)-activation for activation for epithelial-mesenchymal transition (EMT (Montrer ITK Anticorps))-induction.
This study shows that TFAP2C (Montrer TFAP2C Anticorps) promoted lung tumor progression by upregulation of TGFBR1 and consequent activation of PAK1 (Montrer PAK1 Anticorps) signaling.
combined inhibition of ALK5 and CTGF (Montrer CTGF Anticorps) is required to prevent TGFbeta (Montrer TGFB1 Anticorps)-induced nodule formation in tri (Montrer VANGL2 Anticorps)-cellular cultures
Aortic diseases in patients with TGFBR1 or TGFBR2 (Montrer TGFBR2 Anticorps) mutations show the same prevalence of systemic features and the same global survival.
Results show that TGFBR1 expression is regulated in bladder cancer cell through its desumoylation by SENP2.
Low TGFBR1 expression is associated with oral cancer progression.
TGF-beta (Montrer TGFB1 Anticorps) type I, II, and III receptors were all identified in pregnant serum; all were substantially elevated in early-onset but not late-onset preeclampsia. Endoglin (Montrer ENG Anticorps) was increased in both subtypes.
Overexpression of truncated ALK5 in a B-cell line counteracted BMP-7 (Montrer BMP7 Anticorps)-induced apoptosis, whereas overexpression of truncated ALK4 (Montrer ACVR1B Anticorps) had no effect.
Although TGFbeta1 (Montrer TGFB1 Anticorps)/2 receptors are downregulated in breast cancer, their expression in tumors is an indicator of aggressive breast cancer phenotype.
The results indicate that the TGFBR1 gene polymorphism (SNP64) is significantly associated with growth rates including average daily gains between birth and 56 kg, between 5.5 and 56 kg, between 35 and 56 kg.
Report temporal regulation of TGFBR1 mRNA expression in the oocyte, granulosa and theca cells of developing preovulatory follicles in the pig.
TGFbeta (Montrer TGFB1 Anticorps) is abundant in boar seminal plasma, thus TGFbeta (Montrer TGFB1 Anticorps) may be a male-female signalling agent involved in immune changes in the female reproductive tract elicited by seminal fluid.
Porcine transforming growth factor beta receptor 1 has many polymorphisms, including two nonsynonymous substitutions in exons 1 and 7 and novel alternative splicing in exon 3.
isolation and molecular characterization; the full-length TGFBR1 cDNA 1813 bp contains an open reading frame (ORF) of 1512 bp encoding a TGFBR1 protein of 503 amino acids with a calculated molecular weight of 56.4 kDa.
Results show that ALK5 and ALK1 (Montrer ACVRL1 Anticorps) play antagonistic roles in TGF-beta (Montrer TGFB1 Anticorps)-induced podosome formation in aortic endothelial cells.
This study showed that ubiquitinated ALK5 and phosphorylated heat shock protein 27 specifically accumulate in the cytoskeleton fraction, and ALK1 (Montrer ACVRL1 Anticorps) and ALK5 interact with heat shock protein 90 (Montrer HSP90 Anticorps).
GM-CSF (Montrer CSF2 Anticorps) induced airway smooth muscle cells to increase expression of transforming growth factor (TGF)-beta (Montrer TGFB1 Anticorps) receptors type I, II, and III, but had no detectable effect on the release of TGF-beta1 (Montrer TGFB1 Anticorps) by the same ASMC; corticosteroids were inhibitory
ALK5 and Smad4 (Montrer SMAD4 Anticorps) have roles in TGF-beta1 (Montrer TGFB1 Anticorps)-induced pulmonary endothelial permeability
These results indicate that high plasma cholesterol levels may contribute to the pathogenesis of certain diseases (e.g., atherosclerosis) by suppressing TGF-beta (Montrer TGFB1 Anticorps) responsiveness.
Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5.
ALK1 and ALK5 are both essential for correct regulation of VEGF, and that disruption of either pathway leads to disease.
TGF-beta1 (Montrer TGFB1 Anticorps) downregulates caveolin-1 (Montrer CAV1 Anticorps) of cultured endothelial cells, involving ALK-5 receptor subtype
results indicate that CD34 (Montrer CD34 Anticorps)+ cells and signaling through ALK5 play pivotal roles in the morphogenesis of interstitial-like, peritubular-like and cord-like structures
a novel role for SREBP-1 (Montrer SREBF1 Anticorps) as a cell surface retention factor for TbetaRI in mesangial cells, is reported.
a surface population of Hsp90 (Montrer HSP90 Anticorps) extracellularly binds TGFbetaRI and this complex behaves as an active participant in collagen production in TGFbeta (Montrer TGFB1 Anticorps)-activated fibroblasts.
Conditional deletion of Tgfbr1 in PTEN (Montrer PTEN Anticorps)-inactivated endometrium leads to a disease that recapitulates invasive and lethal human endometrial cancer.
fluid shear stress induces autocrine TGF-beta (Montrer TGFB1 Anticorps)/ALK5-induced target gene expression in renal epithelial cells, which is partially restrained by MEK1 (Montrer MAP2K1 Anticorps)/2-mediated signaling.
both GDF-15 (Montrer GDF15 Anticorps) and TGF-beta1 (Montrer TGFB1 Anticorps) counteract chemokine (Montrer CCL1 Anticorps)-induced integrin activation on neutrophils via the ALK-5/TGF-betaRII heterodimer.
CD109 (Montrer CD109 Anticorps) differentially regulates TGF-beta (Montrer TGFB1 Anticorps)-induced ALK1 (Montrer ACVRL1 Anticorps)-Smad1 (Montrer SMAD1 Anticorps)/5 versus ALK5-Smad2 (Montrer SMAD2 Anticorps)/3 pathways, leading to decreased extracellular matrix production in the skin; epidermal CD109 (Montrer CD109 Anticorps) expression regulates dermal function through a paracrine mechanism
miR (Montrer MLXIP Anticorps)-27b is an anti-fibrotic microRNA that inhibits fibroblast activation by targeting TGFbeta (Montrer TGFB1 Anticorps) receptor 1 and SMAD2 (Montrer SMAD2 Anticorps).
In the presence of gadolinium and antibeta1 integrin antibody, collagen regulated the expression levels of Tgfbr1, Tgfbr2 (Montrer TGFBR2 Anticorps) and Smad2 (Montrer SMAD2 Anticorps)/3, but did not alter the phosphorylation of p38 (Montrer CRK Anticorps), ERK1/2 (Montrer MAPK1/3 Anticorps) or JNK (Montrer MAPK8 Anticorps).
miR (Montrer MLXIP Anticorps)-22 acts as a novel negative regulator of angiotensin II-induced cardiac fibrosis by suppressing the expression of TGFbetaRI in the heart.
The protein encoded by this gene forms a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm. The encoded protein is a serine/threonine protein kinase. Mutations in this gene have been associated with Loeys-Dietz aortic aneurysm syndrome (LDAS). Multiple transcript variants encoding different isoforms have been found for this gene.
TGF-beta receptor type I
, TGF-beta receptor type-1
, TGF-beta type I receptor
, activin A receptor type II-like kinase, 53kD
, activin A receptor type II-like kinase, 53kDa
, activin A receptor type II-like protein kinase of 53kD
, activin receptor-like kinase 5
, serine/threonine-protein kinase receptor R4
, transforming growth factor beta receptor I
, transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD)
, transforming growth factor-beta receptor type I
, transforming growth factor, beta receptor 1 (activin A receptor type II-like kinase, 53kDa)
, transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa)
, transforming growth factor beta type I receptor
, transforming growth factor, beta receptor 1
, transforming growth factor beta receptor 1
, activin A receptor type II-like kinase
, transforming growth factor beta receptor type I
, transforming growth factor beta, receptor 1
, type I serine/threonine kinase receptor
, TGF-beta receptor type-1-like
, transforming growth factor, beta receptor I